19 results
424B5
OVID
Ovid Therapeutics Inc
15 Nov 23
Prospectus supplement for primary offering
4:11pm
and produce multiple novel medicines, scale our infrastructure, and thereby succeed in our mission.
S-2
Our Pipeline
The following table sets forth
8-K
EX-99.1
fp137
23 Jun 21
Regulation FD Disclosure
8:05am
8-K
EX-99.1
t1g33k72bhlccfl
13 May 21
Ovid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
4:44pm
8-K
EX-99.1
9ixlnasyunr2baog6om
3 Mar 21
Regulation FD Disclosure
10:05am
8-K
EX-99.1
dw8dm
17 Jun 20
Regulation FD Disclosure
1:11pm
8-K
EX-99.1
9ycioawj1btlqh8y
6 Dec 18
Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome
8:05am
- Prev
- 1
- Next